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The idea that viruses could be useful as selective anticancer agents is not a new one, dating back to almost a century. In recent years, a variety of tumorselective viruses, including over 50 tumor-selective oncolytic adenovirus variants have been tested for antitumor activity in animals and humans. There are three broad approaches to imbuing adenoviruses with tumor selectivity. First, the viral genome can be engineered to limit the expression of essential viral genes to tumor tissues via the use of tumor-or tissuespecific promoters, that is, by transcriptional targeting. This approach, discussed in detail by Ko et al. in this issue, is possible because the expression of the adenovirus genome is a tightly regulated cascade, which can be considered as divided into early (E) and late (L) phases. The E1 region gene products are critical for efficient expression of essentially all the other regions of the adenovirus genome, such that controlling the expression of the E1 region will effectively control adenoviral replication. Oncolytic adenoviruses that utilize this approach include CG7870 , which utilizes prostate-specific transcription regulatory elements to control E1 and target prostate cancer, and CG0070 (Bristol et al., 2003) , which utilizes the human E2F-1 promoter cloned in place of the endogenous E1a promoter to target the diverse group of cancers that have a defective retinoblastoma (Rb) pathway. CG0070 also encodes the cDNA for human granulocyte-macrophage colony-stimulating factor (GM-CSF) in the E3 region. Both of these oncolytic adenoviruses are currently being evaluated in the clinic.
The second approach for engineering tumor specificity entails the deletion of viral gene function(s) that are critical for efficient viral replication in normal cells, but dispensable in tumor cells. O'Shea and McCormick discuss this method further in this issue. Examples include Rb-inactivated E1a-mutated variants such as Addl922-947 and Ad5-D24RGD, and p53-defective E1b-deleted adenovirus variants like Addl1520 (Onyx-015) and Ad5-CD/Tkrep (Bischoff et al., 1996; Freytag et al., 1998; Heise et al., 2000; Johnson, 2002) . These mutants have deletions of the E1a-CR2 and the E1b-55 kD gene regions that are responsible for binding and inactivating Rb family members and p53, respectively. Such viruses were originally believed to target cancer cells with genetic defects in the Rb and p53 pathways, which are defective in most human tumors (Biederer et al., 2002) , but more recent work has shown that differential late viral RNA export in tumor vs normal cells, rather than p53 activation, appears to be the major determinant of the selectivity of Onyx-015 (O'Shea et al., 2004) .
The third approach is based on receptor-mediated targeting of tumor cells through genetic modification of the adenoviral capsid and can be termed transductional targeting; Mathis et al. discuss it in detail in this issue. To successfully create a virotherapy agent using this approach requires ablation of the natural viral uptake mechanism (deselection), identification of tumor-specific receptor targets on cancer cells, and the engineering of new ligands into the viral coat (reselection), all without disrupting viral integrity (Douglas et al., 1999; Alemany and Curiel, 2001; Hemminki et al., 2001; Suzuki et al., 2001) .
The objective of this review is to discuss challenges in manufacturing selectively replicating oncolytic adenoviruses for use in clinical trials and, eventually, commercial use. It focuses on the developmental hurdles for transcriptionally targeted adenovirus variants made with the first strategy, such as CG7870 and CG0070, but most of the hurdles discussed are relevant to the development of any type oncolytic adenovirus and, to a lesser extent, any type of viral-based therapeutic. For more detailed discussions of the basis of adenoviral replication and strategies for its control, the interested reader is directed to Ko et al. and O'Shea et al. (this volume) and several other recently published reviews (Alemany et al., 1999; Biederer et al., 2002; Kirn, 2001; Reid et al., 2002; Yu et al., 2002; Wakimoto et al., 2003) .
Development of oncolytic adenoviruses
As with any drug or biologic product destined for use in humans, oncolytic adenovirus products are subject to broad, yet detailed regulations and must meet a variety of well-defined criteria for purity, potency, stability, and product characterization, among other things. Guidance can be found in the US and EU regulatory documentation and policies for Good Manufacturing Practices (GMP) for making therapeutic products for human use. Particularly relevant are the guidelines for products derived from biotechnology, the latest changes to which have been described in a recent review article (Jones and Levine, 2004) . Although developed specifically for biotechnology-derived products, these guidelines are applicable to the production of oncolytic adenoviruses and other cell-based products, and it is critical to consult them during product development, that is, they are relevant and, perhaps more to the point, they are required. However, since oncolytic adenoviruses are living and, therefore, more variable, less stable and even mutatable, there are consequent unique and significant challenges for their production, a major one being complying with regulatory guidelines for manufacturing and release while producing a living, potentially replicating product. The nature of the dilemma becomes clearer when one considers that the situation is analogous to manufacturing a traditional pharmaceutical or biotechnology-derived protein that hypothetically can reproduce itself, change itself to something else with decreased or increased potency or even with a different biological target, and that either can happen during production or purification or both. This characteristic is perhaps the most significant development challenge for oncolytic adenoviruses. With adenoviruses, the biological and manufacturing consistency of the product depend in large part on the genetic stability of the virus itself as well as the nature of the cell line used to produce the virus. Relevant issues include the generation of recombinant adenoviruses, both replication-competent and replication-deficient, and the detection of wild-type adenovirus contaminants or wild-type virus produced during manufacturing. These unique components of product quality assessment of an adenovirus can be evaluated using a bioamplification assay, that is, an assay that amplifies either pre-existing recombinant replication-competent adenovirus (RCA) variants or wild-type adenovirus and that provides selective pressure to force the expression of genetic instability.
Engineering a stable virus
An unintended effect of engineering tumor-selective adenoviruses is the potential introduction of genomic instability. Wild-type adenoviruses have evolved over the millennia to do their job admirably well: they replicate efficiently in host cells and generate thousands of progeny virions to maintain the infection. The adenoviral genome is stable, yet malleable enough to adapt to new circumstances, and changes that attenuate its replicative ability may result in genomic instability as the adenovirus attempts to revert to wild type. Engineered oncolytic adenoviruses must retain a stable genome for consistent production and biological activity, but engineering an adenovirus to direct its replication preferentially to tumor cells, effectively attenuating its ability to replicate, may introduce significant genomic instability reflecting the effort of the engineered virus to 'recover' from that attenuation.
Overengineering, for example, the introduction of large variations into the adenoviral genome, may result in significant genetic instability that prevents the clinical use of a virus and may lead to recombinants of differing specificity and/or potency, potentially including increased potency beyond that of wild-type adenovirus. Examples of genomic instability are reported in the literature, including dual-promoter-controlled viruses in which the same promoter is used twice in a single adenoviral backbone to improve tumor selectivity. In the Calydon/Cell Genesys, Inc. (CGI) virus CV716, E1a and E1b are independently controlled by separate PSE elements Henderson and Yu, 2002) . Tumor selectivity was improved; compared to the single PSE-controlled oncolytic adenovirus CG7060, the prostate specificity of CV716 was increased over 100-fold. Southern blot analysis, however, revealed selfinactivation of the virus due to homologous recombination between the two identical inserted TREs. No effort to assess changes in viral potency was reported in this study. Similarly, the use of homologous controlling elements in Onyx-411 results in recombination of the viral backbone to self-inactivating recombinants as well as to recombinants with undetermined changes in potency and specificity (Shen, 2003) . In contrast, the use of heterologous promoters to control the E1a and E1b transcription units results in a more genetically stable virus, for example, CG7870, in which E1a is controlled by the rat probasin promoter and E1b by PSE (Yu et al., 1999; Henderson et al., 2001 ). However, OAS403, an oncolytic adenovirus developed by Genetic Therapy, Inc. (GTI), uses heterologous promoters but is not genetically stable. In this variant, the E2F-1 promoter controls expression of the E1a transcription unit and the hTERT promoter drives the expression of the E4 transcription unit, plus the packaging signal has been relocated from the left to the right end of the genome and a polyadenylation signal has been inserted upstream of the E1a promoter (Ryan et al., 2004) . Although highly tumor-selective, quality testing revealed a set of four or more recombinants detectable after serial amplification through a nonpermissive cell line (see discussion of this type of assay below). The recombinants had altered selectivity and decreased potency. Sequence analysis revealed the presence of the packaging signal at both the right and left ends of the genome, plus the relocation of an indeterminate set of adjacent E4 sequences to the left end, suggestive of rearrangement by either intermolecular recombination or polymerase jumping (GTI and Cell Genesys, Inc., unpublished data). Further work with other E4-altered adenoviruses that retain the packaging signals in its native left-end position suggested that E4 modifications alone were sufficient to induce an unacceptable degree of genomic instability (Yu and Li, unpublished) , and this engineering approach has been abandoned.
The genomic instability of engineered adenoviruses will be most evident in vivo, where many of the infected cells will be nonpermissive for replication of tumorselective adenoviruses. The selective pressure imposed may result in the emergence of more efficient or nonselective and possibly detrimental variants. It is therefore critical to assess the genetic stability of the candidate adenovirus early in development using serial viral passaging in nonpermissive cells in vitro to assess genome stability in a bioamplification assay. The use of nonpermissive cells mimics the situation in which a tumor-selective oncolytic adenovirus infects a normal, nontumor cell.
Bioamplification assays
Semiquantitative bioamplification systems are used to detect recombination that may occur during manufacturing. These assays are able both to detect contaminating wild-type adenovirus and evaluate the genomic stability of an engineered adenovirus. The viral material tested in such assays requires multiple rounds of infection (passages). Amplification is initiated by infection of permissive or nonpermissive cells (depending upon the objective of the assay) with the purified working virus stock, which represents passage 0 (p0). After several days of growth, the infected cells are harvested for viral purification using a CsCl gradient centrifugation method, or, alternatively, a clarified viral lysate (CVL) is prepared. An aliquot of purified virus or of the CVL is used to infect the cells for the next passage. The process is repeated for several passages, with four passages (p4) typically providing acceptable sensitivity. Permissive cells (preferably those that serve as producer cells during production) are used to estimate the potential for recombination during the manufacturing process or to amplify any contaminating wild-type virus to detectable levels. Nonpermissive cells are used to assess the genetic stability of the engineered virus since they provide selective pressure as described above. Both pre-existing recombinants and those generated during passaging can be detected by PCR and/or restriction digestion if the structure of the potential recombinant is known or can be predicted a priori. Altered potency in late-passage virus, which indicates that there has been a significant change in the viral population, can be detected using a standard set of in vitro cytotoxicity assays.
Assessment of viral genetic stability and detection of wild-type adenovirus
Wild-type adenovirus that contaminates a preparation of engineered oncolytic adenovirus is typically detected using quantitative or real-time PCR techniques (Bernt et al., 2002) . The specificity of the assay for wild-type adenovirus is conferred by the use of a forward primer that hybridizes at the junction between the E1a promoter and E1a gene in the case of an E1-controlled engineered virus like CG0070 for example. In CG0070, this junction is eliminated by deletion of the endogenous E1a promoter and subsequent insertion of the E2F-1 promoter. Whereas both wild-type adenovirus and CG0070 can hybridize with the probe and the reverse primer, only adenoviruses containing the wild-type E1a promoter-E1a gene junction are expected to hybridize with the forward primer, initiate DNA polymerization, and produce a PCR signal, which is therefore indicative of the presence of wild-type adenovirus. However, the level of sensitivity of the PCR method, about one wildtype adenovirus in 10 6 -10 8 viral particles (the latter less common and only for shorter PCR products) is rather low considering that clinical doses are in the range of 10 12 viral particles per patient. Greater sensitivity can be achieved using a bioamplification assay in nonpermissive cells (i.e. cells that are minimally permissive for the engineered oncolytic adenovirus and maximally permissive for wild-type). The selective pressure associated with passage in nonpermissive cells in vitro also provides a sensitive method to monitor genetic stability of an engineered adenovirus. Nonpermissiveness for the tumor-selective adenovirus is not absolute, however, with varying degrees of selectivity among various cell lines. For example, the assay could be based on monitoring the preferential replication of wild type (or wild-typelike recombinants) in an oncolytic adenovirus preparation in WI-38, a normal lung fibroblast cell line. WI-38 cells provide a three-log selectivity factor between wildtype and engineered adenoviruses in the case shown (Figure 1 ), but this factor is likely to vary among different oncolytic adenoviruses. As a result, the nonpermissive cell line must normally be selected specifically for each individual engineered virus to maximize both selective pressure and the degree of selectivity. This form of the assay maximizes the likelihood of detecting wild-type adenovirus in the oncolytic adenovirus product, with a typical bioamplification assay able to detect the equivalent of one wildtype adenovirus in 10 8 -10 9 viral particles of oncolytic adenovirus, a two-to three-log improvement over the PCR-based assay.
Amplification in nonpermissive cells is also the method of choice for detecting genomic instability, since multiple serial passages in nonpermissive cells applies selective pressure similar to that in vivo, such that unstable viruses may be subject to modifications that affect biological activity detectable using an in vitro cytotoxicity assay. Other assays, including PCR and restriction digestion, can provide additional information on the nature of the recombinant(s), if any, but the quickest, and arguably the more relevant way to detect recombinants is the cytotoxicity assay. Figure 2 illustrates the outcome of cytotoxicity testing of three different oncolytic adenoviruses. As shown in Figure 3 , in all three variants the E2F-1 promoter drives the E1a transcription unit. In two of them (Var1 and Var3) the E4 transcription unit is controlled by the hTERT promoter; in the other (Var2) hTERT controls E1b. The packaging signal is relocated next to the right-end ITR in Var1, whereas it remains in its native left-end position in the other two. All three variants were independently taken through four passages of amplification in nonpermissive WI-38 cells, which will exert selective pressure on the attenuated virus. Virus from the final p4 passage was purified and used in cytotoxicity tests in A549, SW780, or WI-38 cells. Data from the A549 cytotoxicity assay are shown in Figure 2 . Viability curves were left-shifted in the Var1 and Var3 p4 virus preparations, indicating that a significant increase in potency for the virus had occurred and suggesting that a substantial fraction of the virus population represented recombinant forms. The potency of Var2, on the other hand, was not increased, signifying that it had a relatively stable genome under the conditions of the assay. Essentially identical results were seen with the other two cell lines with the three variants. These findings suggest that modification of the E4 region, or, more generally, the right-end of the viral genome will result in a more genetically unstable adenovirus and should therefore be avoided if possible.
Assessment of potential for recombination during production
Multiple serial passages in permissive cells such as A549 or HeLa-S3 can be used to mimic the manufacturing conditions as a means to evaluate viral stability under these conditions. Cell lines selected for this test should be identical to the producer cell line that will be used in Product development of oncolytic adenoviruses PK Working et al the manufacturing process to get an accurate assessment of recombination potential during production. As described above, virus is purified after four serial passages, and the viral genome and viral biological activity are compared to the corresponding p0 virus by various assays, including PCR, to detect the generation of recombinant viruses and cytotoxicity assays to determine potency changes suggestive of a shift in viral biological activity. In the PCR work, primer sets are chosen to detect likely recombinant viruses. In the case of the Var1 virus described above (Figure 3) , multiple primers to detect relocation of the right end of the viral DNA (including the packaging signal) to the left would be selected, since such a relocation would amount to a potential restoration of the wild-type genome. The modified E1 region of this virus would be considered the most likely focus for potential recombination events. PCR analysis of Var1 using several different primers after bioamplification revealed unexpected bands representing recombinants; a typical example is shown in Figure 4 . Based on the known binding sites of the primers in the Var1 genome, these likely represent relocations of the right-end packaging signal to the left side of the genome. DNA sequence analysis on several of the PCR products confirmed that the recombinants contained a translocation of the right-end DNA fragment to the left end of the viral genome in the E1 region. A caveat here is that one may not detect recombinant that one cannot predict, since the appropriate PCR primers must be used to detect changes.
Once a producer cell line is selected and the viral genomic stability is deemed acceptable, one confronts the necessity to consistently manufacture large quantities of the oncolytic adenovirus for use in clinical testing.
Manufacturing overview
Manufacturing an adenovirus requires a Master Cell Bank (MCB) of a producer or packaging cell line; a Master Viral Bank (MVB) of the virus; defined and optimized culture conditions for viral growth and harvest; an effective, efficient, and reproducible downstream purification process; and the identification of an injectable final formulation in which the virus will be stable for long periods in storage. MCBs begin with a seed stock, or development bank, of well-characterized cells of the type selected for production, which is expanded to produce the MCB; selection of an appropriate producer cell is discussed further below. Similarly, a well-characterized, genetically stable seed stock of engineered virus is expanded under controlled conditions to produce an MVB.
Once produced, an array of validated assays by which to qualify the MCB and MVB, as well as demonstrate the consistency of the manufacturing process (i.e. to show that the virus meets a predefined set of specifications), is required so that the virus can be characterized and released, as described in more detail below. However, the first critical decision in manufacturing a viral product is the selection of an appropriate cell line to serve as the producer cell, which will not only serve as the biological foundation of the manufacturing process, but also be used to maintain a stable MVB.
Producer cells
The producer cell line used to grow the virus must meet certain criteria. First, they obviously must be permissive for viral replication. For a replication-defective adeno- (Hehir et al., 1996; Smith and Eck 1999; Murakami et al., 2002) . For a replication-defective adenovirus, the recombinant RCA may, for example, be a wild-type virus that still carries the inserted transgene of the replication-deficient variant and thereby raises safety concerns. FDA has set a limit for the presence of RCA in replication-defective adenoviral vectors, and standard biological assays have been established to detect RCA. The selection of the proper producer cell line can go a long way to address this concern. Among the most widely used cell lines are 293 cells (Graham et al., 1977) , derived from infecting human embryonic kidney cells with sheared adenovirus DNA. These cells contain a long integrated copy of viral sequences, including the E1a and E1b genes and their native promoters, the adenoviral inverted terminal repeat (ITR), and the packaging signal. The extensive sequence homology between the engineered adenoviruses and the integrated adenovirus sequences of the 293 cells gives rise to RCA recombinants. The PER.C6 cell line (Fallaux et al., 1998) , derived from human embryonic retinoblast cells and carrying a shorter adenoviral sequence containing the native E1a/E1b sequences with the E1a promoter replaced by a PGK promoter, was developed to reduce the frequency of RCA recombinants during production. PER.C6 cells are reported to have produced no RCA in over 40 largescale batches of adenovirus (Lusky, 2005) , although there are reports of the generation of replicationdeficient recombinants that cause cytopathic effects (CPE) (Murakami et al., 2002 (Murakami et al., , 2004 . More recently, a novel cell line (C139) derived from A549 human lung cancer cells has been reported (Farson et al., 2004 (Farson et al., , 2005 . In this cell line, the E1a and E1b coding regions were reduced to their minimal sequences and their native promoters removed. The sequences were then introduced in the A549 cells using separate MLV vectors to ensure noncontinuous integration into the genome.
Although not yet utilized in large-scale production runs, extensive intermediate-scale laboratory studies using serum-free suspension culture of this E1A/E1B-complementing cell line have demonstrated that neither RCA nor CPE-inducing replication-deficient recombinants are generated when replication-deficient adenoviruses are produced, in contrast to both 293 and PER.C6 cells.
Producer cells for replication-competent oncolytic adenoviruses must meet other tests. Both the 293 and PER.C6 systems have been used for production of oncolytic adenoviruses, but since oncolytic adenoviruses are replication-competent, undesirable recombinants are not limited to wild-type virus, that is, the issue is not strictly the generation of RCA but instead potential recombination to produce wild-type adenovirus or other replication-competent adenoviral variants that may exhibit greater potency or altered trophism or both. Recombinants may be replication-competent or even helper-dependent replication-defective viruses. Regardless of the type(s) of recombinants, their presence is likely to have a negative impact on tumor selectivity, potency, and overall product safety and efficacy. The generation of RCA and recombinants is closely related to both the basic genomic stability of the engineered oncolytic adenovirus and the producer cell line used. Since multiple serial expansion passages in the permissive producer cells are required to manufacture an oncolytic adenovirus, each passage provides an opportunity for recombination to produce undesirable recombinants, particularly if extensive sequence homology exists between the vector construct and the producer cells.
Thoughtful selection of the producer cell used for manufacturing can decrease the potential for recombination during the manufacturing process. Utilization of 293 cells, for example, with their extensive adenoviral sequence homology, is likely to result in a high rate of recombination. Designing a production plan that maintains the MVB and working viral banks in a tumorspecific cell line, for example, using the PSA-positive LNCaP cell line for production of the PSE-controlled, prostate-specific adenovirus CG7060 can significantly reduce the potential for recombination and permit production of clinical material of acceptable quality. In the case illustrated, to minimize wild-type virus production, LNCaP cells were used to both expand the seed virus and to produce the MVB itself; 293 cells were used for the final large-scale production of CG7060 (Table 1) . It is likely that the wild-type adenoviral titers seen in this series of studies represent the expansion of pre-existing wild-type contamination of the CG7060 seed stock or MVB (compare results using 293 vs LNCaP as MVB cell line), not recombination during production. Nonetheless, this approach requires the characterization and maintenance of two cell banks: an LNCaP bank for supporting the viral banks and a 293 producer cell bank for manufacturing, doubling both the effort and characterization costs. Therefore, the selection of production and MVB cell lines that do not have integrated adenoviral sequences is more efficient and cost effective, and, more importantly, can further Count of wild-type adenovirus in indicated titer of CG7060. Indicated cell lines were used to produce the seed virus prior to the MVB, to manufacture the MVB, and in the production of the adenoviral product. LNCaP is a PSApositive prostate cancer cell line; CG7060 is a prostate-specific, PSEcontrolled oncolytic adenovirus decrease the potential for recombination during production, so it is probably safer.
Once selected and characterized, the producer cell line must be made into an acceptable MCB and MVB.
Master cell and virus banks
MCBs and MVBs are subject to demanding characterization and extensive quality control and must comply with established regulatory guidelines (FDA, 'Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals', CBER, 1993; ICH Q5D, 'Derivation and Characterisation of Cell Substrates Used for Production of BioTechnological/Biological Products'). A nonexhaustive list of characterization and release criteria for MCBs and MVBs would include appearance, identity, cell count and viability (MCB only), particle and infectious titer (MVB only), sterility, mycoplasma, purity, absence of adventitious viral agents and replication competent virus, absence of specific human viral pathogens (CMV, HIV-1, HIV-2, HBV, HCV, etc.), and more as detailed in the guidelines. Every product may also have Manufacturer's Working Banks of producer cells and virus (MWCB and MWVB) for production purposes, each of which will have a similar rigorous, although generally somewhat abbreviated, list of characterization criteria.
Production process
Although the exact details will vary, oncolytic adenoviruses are typically made and purified using the general scheme illustrated in Figure 5 . In brief, a vial of the MCB or MWCB is expanded to sufficient cell number and infected with aliquots of the MVB, MWVB, or with a CVL produced in a preliminary incubation of producer cells and aliquots of the MVB. In the absence of an MWVB, the use of a CVL extends the lifetime of the MVB via an early expansion to an intermediate scale for inoculation of the final production run. After sufficient culture time for viral amplification (generally 2-5 days), virus-containing producer cells are lysed by detergent or freeze-thaw cycles, and the resulting lysate is clarified via filtration. The lysate is typically further treated, for example, with Benzonase to digest free unincapsidated RNA and DNA. Virus purification and removal of process contaminants such as host cell proteins and medium components is typically carried out using anion-exchange (AEX) capture and sizeexclusion chromatography (SEC); many processes further utilize a diafiltration concentration and buffer exchange step to concentrate the virus in the final formulation buffer. The formulated virus is then sterilefiltered and filled and finished into suitable pharmaceutical containers. A comprehensive description of manufacturing, including a detailed treatment of vector quantification, quality control, and GMP regulations as they apply to producing replication-deficient adenoviruses was recently published (Lusky, 2005) and should be consulted for more details.
Once the oncolytic adenovirus is produced, the challenge becomes demonstrating the consistency of the manufactured product using a set of appropriate and qualified analytical techniques.
Characterization, testing, and release of oncolytic adenoviruses
The regulatory guidelines provide a 'generic' list of the release criteria that are useful for oncolytic adenoviruses and, where not specific, analogies to release criteria for Figure 5 Typical manufacturing scheme for an oncolytic adenovirus Product development of oncolytic adenoviruses PK Working et al biotechnology-derived product and even small molecules can be useful (Table 2 ). In general, the oncolytic virus product will be characterized for identity, purity, and the presence of contaminating adventitious agents according to ICH Q5D, 'Derivation and Characterisation of Cell Substrates Used for Production of BioTechnological/Biological Products' and ICH Q5A, 'Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin'. However, more specific criteria that address the precise nature of the oncolytic adenovirus and its method of production must be developed for individual viral products. These additional criteria can range from obvious criteria tailored to detect a known process residual, to a requirement to develop expanded potency measurements for an 'armed' virus. Two criteria may pose special challenges and are addressed in more detail in the following subsections. The first, applicable to all adenoviral vectors, is the development of an assay or assays to define the potency of the virus, which will include both the ratio of physical to infectious titer as specified by the regulatory authorities and other assays if the virus carries a transgene of some sort. Examples of the latter include cases in which the oncolytic adenovirus encodes a gene for a prodrug-activating enzyme, a chemosensitizer, a cytokine, or virtually any other biologically or chemically active molecule. The second, which is more relevant to oncolytic adenoviruses, is selectivity, that is, how discriminating is the virus for tumor cells compared to normal, nontumor cells? Selectivity is directly related to potency, as it is a measurement of 'relative' potency.
Potency assays
A standard potency assessment for an oncolytic adenovirus is the ratio of physical particles to infectious particles in the test material. In other words, how much of what is in the product vial is actually living, infectious adenovirus? For replication-defective adenoviral vectors, the ratio of noninfectious particles to infectious particles is specified to be p30 : 1 in the US; details are provided in the regulatory documents referenced above. Although no specific guidance exists on the acceptable physical/infectious particle ratio for replicating vectors, the 30 : 1 ratio is generally adopted. Measurement of physical titer is straightforward, typically accomplished using a chromatographic separation method with detection of viral particles or absorbance at 260 nm in the presence of detergent. Assessment of infectious titer is likely more virus-specific, since one must utilize a cell type or types that is permissive for the engineered virus. Infectious titer is most commonly measured by determining plaque forming units/cytopathic effects (CPE) in permissive cells. In these assays, serial dilutions of virus are used to infect permissive cells; CPE can be measured by observing the formation of lytic plaques on a lawn of infected cells (plaque assay) or by microscopic observation of infected cell culture wells in a limiting-dilution format (TCID 50 ). Other measurements of infectious titer include quantification of proteins or sequences derived from either the vector (i.e. hexon) or the transgene in infected cell cultures. A wild-type serotype 5 adenovirus reference standard, produced via a collaboration of industry, academia, and the FDA, is available from ATCC. It can be useful for normalizing interlab assay differences, as the exact methods for infectious titer assay vary among labs. Potency assessments must be expanded when the oncolytic adenovirus is armed. In the case of CG0070, which carries the cDNA for human GM-CSF, resulting in production of active cytokine from transduced cells, assays were developed to measure both the amount and bioactivity of the cytokine produced after transduction of the target cells. GM-CSF secretion after transduction of target cells in vitro is measured using a quantitative sandwich ELISA, and GM-CSF bioactivity is quantified using a cell-based proliferation assay that utilizes the TF-1 erythroleukemia cell line, which is known to be dependent upon GM-CSF for growth (Kitamura et al., 1989) . In the presence of bioactive GM-CSF, TF-1 cells become metabolically active and proliferate. The increased metabolic activity of the proliferating cells can be measured by the addition of a fluorogenic redox indicator (Alamar Blue) to the cultures or by the more traditional thymidine incorporation assay. GM-CSF bioactivity is expressed as a percent activity of a product reference control, which must be established, typically using an early production lot that has been extensively characterized and is considered representative of the product, and which should be calibrated against the World Health Organization (WHO) GM-CSF standard (GM-CSF First International Standard, OMS Report No. 840, 1994) . As with any analytical assay, the GM-CSF bioactivity assay should also be characterized in terms of intra-and interassay precision, accuracy, and linearity as part of its qualification as a release specification. It should be noted that assays of biological activity are particularly prone to assay variability. For this reason, specification limits for potency of biologicals are often set for both the potency of the product (acceptable limits around the stated potency are 80-125% for marketed recombinant GM-CSF, for example) and the assay (confidence limits of the assay). Since it is not uncommon for biological assays to have a high relative standard deviation (e.g. 20-50%), the confidence limits of the assay tend to be wide.
Analogous bioactivity assays will be necessary for any oncolytic adenovirus that results in the secretion of any biologically active molecule, for example, an assay to determine the specific activity of a prodrug-activating enzyme. In advanced stages of development, these assays may become part of the release criteria for the oncolytic adenovirus product.
Selectivity assays
These assays are designed to demonstrate that the manufactured oncolytic adenovirus consistently demonstrates its intended selectivity for tumor cells relative to nontumor cells. Selectivity is fundamentally a relative expression of virus potency, as the biological activity of the virus in tumor cells is compared to its activity in normal, nontransformed cells (Figure 1 illustrates such preferential activity). As such, a measurement of selectivity can take different forms, depending on the method chosen to measure virus potency. Selectivity can be expressed as a ratio. For example, if potency is measured by a TCID 50 assay, selectivity can be expressed as:
Selectivity Ratio ¼ TCID 50 in normal cells TCID 50 in tumor cells A Selectivity Ratio >1 indicates that the virus replicates better (preferentially) in tumor cells, or, considered from a different perspective, that virus replication is attenuated in normal cells compared to tumor cells. The higher the ratio, the more selective, and consequently safe, is the virus. This interpretation is based on the important assumption that the virus has equal opportunity to infect and enter both the tumor and normal cells in which viral replication is compared; in other words, the pair of cells used for the comparison must express similar levels of adenovirus receptors. Ideally, a matched pair of normal and transformed cells of common origin should be used, although such reagents are unlikely to be readily available. An alternative approach is to normalize both measurements to wild-type adenovirus, so that differences in permissiveness to adenovirus infection between the normal and tumor cell lines are taken into account. The Selectivity Ratio would then take the following form:
Normalized Selectivity Ratio This reciprocal ratio is referred to as the Selectivity Index (SI; Haviv and Curiel, 2003) . While the use of wild-type adenovirus in a laboratory producing or testing an oncolytic virus is certainly not desirable, the use of wild-type virus to identify a pair of tumor/normal cell lines with comparable permissiveness during assay development and qualification is essential to the correct interpretation of selectivity results. Once an appropriate pair of cell lines is identified, the selectivity assay can become a relevant measurement of the clinical safety of the oncolytic virus.
Conclusions
Engineered oncolytic adenoviruses can be produced in large quantity and to accepted pharmaceutical standards using the available regulatory documents as general guidelines. These documents, although developed principally for biotechnology-derived products, provide a useful roadmap for the production and characterization of oncolytic adenoviruses for human use. Manufacturing processes and development of appropriate characterization assays should be sciencedriven and be designed to answer specific questions using the best available science and technology, keeping in consideration the unique nature of the product: a living, and mutatable, virus. Particular attention should be directed towards understanding the associated unusual challenges of product development in such a setting, most notably the potential instability of engineered constructs (as evidenced by their occasional reversion to wild-type format) as well as the impact of the details of the manufacturing process, including the producer cell line used, on final product quality. These challenges notwithstanding, designing a rational and science-based development program has the promise of delivering an ample supply of well-characterized, selective, and potentially potent oncolytic adenoviruses.
